Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
FBCG vs XBI: how they differ
FBCG and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
Fidelity Blue Chip Growth ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, FBCG and XBI hold 0% of their money in the same securities at the same weight.
| Only in FBCG | Only in XBI |
|---|---|
| NVIDIA CORP 14.62% | MODERNA INC 2.87% |
| APPLE INC 9.64% | TWIST BIOSCIENCE CORP 1.81% |
| ALPHABET INC 9.10% | HALOZYME THERAPEUTICS INC 1.47% |
| AMAZON.COM INC 8.43% | NATERA INC 1.46% |
| MICROSOFT CORP 5.20% | KYMERA THERAPEUTICS INC 1.45% |
| META PLATFORMS INC 3.90% | TRAVERE THERAPEUTICS INC 1.40% |
| BROADCOM INC 3.74% | ROIVANT SCIENCES LTD 1.39% |
| ELI LILLY and CO 2.25% | ORUKA THERAPEUTICS INC 1.38% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Sep 10, 2026.
| FBCG Fidelity Blue Chip Growth ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Fidelity | State Street |
| What it is | Blue Chip Growth | SPDR S&P Biotech |
| Total return, 1 year | +17.3% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −0.2 pts | +46.5 pts |
| Expense ratio | 0.57% | 0.35% |
| Already in the S&P 500 | 86.8% | 8.5% |
| Holdings | 214 | 154 |
FBCG in plain words
FBCG is an index equity fund tracking the Blue Chip Growth. Over the year to Sep 11, 2026 it returned +17.3% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.57% a year. By its holdings filed for Apr 30, 2026, 87% of the fund by weight is stocks the S&P 500 also holds, across 214 positions, with the top ten at 61.2%. It sat 3.7% below its high of Jun 2, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, FBCG or XBI?
- In the year to Sep 13, 2026, with distributions reinvested, FBCG returned +17.3% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, FBCG or XBI?
- FBCG charges 0.57% a year and XBI charges 0.35%, so XBI is cheaper. Fees come from each fund's prospectus.
- How much do FBCG and XBI overlap with the S&P 500?
- By their latest filed holdings, 87% of FBCG and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, FBCG against XBI, data as of Sep 13, 2026. https://etfiq.com/compare/any/fbcg-vs-xbi Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources